Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00503295 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
A Phase 2 study, sponsored by Oncolytics Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT00503295 is a Phase 2 study that has completed, run by Oncolytics Biotech. The registered enrollment target is 53 participants.
The verdict
NCT00503295, a Phase 2 study, has completed, sponsored by Oncolytics Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN® therapeutic reovirus is safe and effective in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung.
Interventions
- BIOLOGICAL REOLYSIN®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2007-06 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00503295
The ClinicalTrials.gov registry entry for NCT00503295 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oncolytics Biotech, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which REOLYSIN® is the first listed.
NCT00503295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00503295 about?
NCT00503295 is a clinical study titled "Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung". The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN® therapeutic reovirus is safe and effective in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung.
What is the current status of trial NCT00503295?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2007-06. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00503295?
The interventions under investigation include: REOLYSIN® (BIOLOGICAL).
Who is sponsoring clinical trial NCT00503295?
This trial is sponsored by Oncolytics Biotech, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.